[Clinical usefulness of serum sialyl Le(x)-i measurement in patients with ovarian cancer].
Sialyl Le(X)-i (Sialyl SSEA-1, SLX) is one of the type 2 chain carbohydrate antigens, which is defined by a monoclonal antibody FH-6. The clinical usefulness of the measurement of serum Sialyl LeX-i levels in the follow-up study of outpatient with ovarian cancer was examined for the early detection of recurrence as the serodiagnostic test. Elevated serum Sialy Le(X)-i levels (more than 38 unit/ml) were observed before treatment in 7 of 12 patients with a good prognosis (group A) and in 15 of 26 patients with a poor prognosis (group B). Six (85.7%) in 7 patients with elevated serum Sialyl Le(X)-i levels in group A decreased to the normal range after treatment, whereas 3 (20.0%) in 15 patients with positive serum Sialyl Le(X)-i levels in group B decreased below 38 unit/ml a after treatment. In 9 (34.6%) in group B, elevated serum Sialyl Le(X)-i levels were observed with an average 3.1 weeks before clinical evidence of recurrence. With tumor progression, serum Sialyl Le(X)-i levels also rose in 25 (96.2%) in group B. In 4 (15.4%) in group B, serum Sialyl Le(X)-i levels were a useful tumor marker compared with others including CA 125, TPA, and CEA. Consequently, the measurement of serum Sialyl Le(X)-i levels may be useful to monitor the condition of the disease, presume progression, and detect recurrence early in outpatients with ovarian cancer.